{"id":"NCT05399485","sponsor":"Pfizer","briefTitle":"Efficacy and Safety Study of Rimegepant for Migraine Prevention in Japanese Subjects (Japan Only)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Rimegepant for Migraine Prevention in Japanese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-09","primaryCompletion":"2024-01-18","completion":"2024-11-07","firstPosted":"2022-06-01","resultsPosted":"2025-07-14","lastUpdate":"2025-08-13"},"enrollment":496,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Rimegepant","otherNames":["BHV3000"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rimegepant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being conducted to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the prevention of migraine.","primaryOutcome":{"measure":"Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase","timeFrame":"Baseline, Week 9 to Week 12 of the DBT phase","effectByArm":[{"arm":"Rimegepant","deltaMin":-2.4,"sd":null},{"arm":"Placebo","deltaMin":-1.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0021"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":44,"countries":["Japan"]},"refs":{"pmids":["40542538"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=BHV3000-309"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":247},"commonTop":["Nasopharyngitis","COVID-19","Oropharyngeal pain","Pyrexia","Influenza"]}}